SCS(SH:601555) Zhong Guo Jing Ji Wang·2025-10-25 09:27Group 1 - The Beijing Stock Exchange's listing committee approved Jiangsu Aisheren Medical Technology Group Co., Ltd. for IPO, marking the 64th company approved this year [1] - Aisheren specializes in the research, production, and sales of disposable medical consumables for rehabilitation and medical protection, primarily through ODM/OEM for international brands [1] - The company plans to issue up to 16,919,834 shares, with a potential 15% over-allotment option, aiming to raise 30 million yuan for the construction of a public health medical supplies industrial park [2] Group 2 - The main underwriter for Aisheren's IPO is Dongwu Securities, which has successfully sponsored two IPO projects this year [1] - Aisheren's largest shareholder, Jiangsu Novick, holds 79.58% of the company's shares, with Zhang Yong controlling a total of 88.69% [1] - The review meeting raised inquiries regarding the stability of sales with the primary customer, Medline Group, and the impact of foreign trade policies and exchange rate fluctuations on the company's performance [3][4] Group 3 - The review committee requested further clarification on the authenticity and sustainability of sales with Medline Group, as well as the rationale behind the increased procurement from foreign suppliers [4] - The committee also inquired about the technological innovation and competitive advantages of Aisheren's core products, including the existence of technological barriers [4] - Concerns were raised regarding the investment efficiency of the fundraising projects and the company's plans for capacity utilization post-project completion [4]